Correlation Between Crispr Therapeutics and United Therapeutics

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and United Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and United Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and United Therapeutics, you can compare the effects of market volatilities on Crispr Therapeutics and United Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of United Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and United Therapeutics.

Diversification Opportunities for Crispr Therapeutics and United Therapeutics

0.66

Correlation Coefficient

Crispr Therapeutics  United Therapeutics

Poor diversification

The 3 months correlation between Crispr and United is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and United Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on United Therapeutics and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with United Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of United Therapeutics has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and United Therapeutics go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and United Therapeutics

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 1.67 times more return on investment than United Therapeutics. However, Crispr Therapeutics is 1.67 times more volatile than United Therapeutics. It trades about 0.08 of its potential returns per unit of risk. United Therapeutics is currently generating about 0.05 per unit of risk. If you would invest  4,552  in Crispr Therapeutics AG on September 3, 2024 and sell it today you would earn a total of  565.00  from holding Crispr Therapeutics AG or generate 12.41% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Crispr Therapeutics AG  vs.  United Therapeutics

Crispr Therapeutics

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Crispr Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

United Therapeutics

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in United Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable technical indicators, United Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Crispr Therapeutics and United Therapeutics

The main advantage of trading using opposite Crispr Therapeutics and United Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, United Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will offset losses from the drop in United Therapeutics' long position.

The idea behind Crispr Therapeutics AG and United Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.